Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
22.43
-1.51 (-6.31%)
At close: Mar 3, 2026, 4:00 PM EST
22.00
-0.43 (-1.92%)
After-hours: Mar 3, 2026, 7:04 PM EST
Arcus Biosciences Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Arcus Biosciences stock have an average target of 30.3, with a low estimate of 14 and a high estimate of 56. The average target predicts an increase of 35.09% from the current stock price of 22.43.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arcus Biosciences stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 2 | 1 | 2 |
| Hold | 2 | 2 | 2 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $36 → $49 | Buy | Maintains | $36 → $49 | +118.46% | Mar 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +42.67% | Mar 2, 2026 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $30 → $23 | Buy → Hold | Downgrades | $30 → $23 | +2.54% | Feb 12, 2026 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $16 → $28 | Hold → Strong Buy | Upgrades | $16 → $28 | +24.83% | Jan 13, 2026 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $23 → $20 | Buy → Hold | Downgrades | $23 → $20 | -10.83% | Jan 8, 2026 |
Financial Forecast
Revenue This Year
122.68M
from 247.00M
Decreased by -50.33%
Revenue Next Year
147.14M
from 122.68M
Increased by 19.94%
EPS This Year
-4.01
from -3.29
EPS Next Year
-3.54
from -4.01
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 253.0M | 296.2M | |||
| Avg | 122.7M | 147.1M | |||
| Low | 6.9M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.4% | 141.4% | |||
| Avg | -50.3% | 19.9% | |||
| Low | -97.2% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.33 | -3.12 | |||
| Avg | -4.01 | -3.54 | |||
| Low | -4.75 | -3.99 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.